NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.00 0.00 (0.00 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$16.00
Today's Range$15.46 - $16.61
52-Week Range$6.13 - $17.56
Volume91,687 shs
Average Volume124,735 shs
Market Capitalization$331.14 million
P/E Ratio-3.33
Dividend YieldN/A
BetaN/A

About Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals logoAllena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577

Debt

Debt-to-Equity Ratio0.06
Current Ratio12.06
Quick Ratio12.06

Price-To-Earnings

Trailing P/E Ratio-3.33
Forward P/E Ratio-8.33
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.64 per share
Price / Book4.40

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees34
Outstanding Shares20,700,000

Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals (NASDAQ:ALNA) issued its earnings results on Tuesday, May, 8th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.05. View Allena Pharmaceuticals' Earnings History.

What price target have analysts set for ALNA?

6 brokers have issued 1-year target prices for Allena Pharmaceuticals' shares. Their forecasts range from $21.00 to $61.00. On average, they expect Allena Pharmaceuticals' share price to reach $32.90 in the next year. View Analyst Ratings for Allena Pharmaceuticals.

What are Wall Street analysts saying about Allena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (5/11/2018)
  • 2. Wedbush analysts commented, "We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset." (12/18/2017)

Who are some of Allena Pharmaceuticals' key competitors?

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the folowing people:
  • Dr. Alexey L. Margolin Ph.D., Co-Founder, CEO & Director (Age 65)
  • Dr. Louis Brenner, Pres & COO (Age 48)
  • Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 58)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 53)
  • Mr. Hugh Wight, VP of Technical Operations

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

When did the company's lock-up period expire?

Allena Pharmaceuticals' lock-up period expired on Tuesday, May 1st. Allena Pharmaceuticals had issued 5,333,333 shares in its public offering on November 2nd. The total size of the offering was $74,666,662 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Has Allena Pharmaceuticals been receiving favorable news coverage?

Media stories about ALNA stock have trended somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Allena Pharmaceuticals earned a media sentiment score of -0.08 on Accern's scale. They also assigned news articles about the company an impact score of 44.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (1.98%), BlackRock Inc. (1.12%), JPMorgan Chase & Co. (0.95%), Millennium Management LLC (0.44%), Citadel Advisors LLC (0.05%) and Wells Fargo & Company MN (0.05%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals.

Which institutional investors are selling Allena Pharmaceuticals stock?

ALNA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for Allena Pharmaceuticals.

Which institutional investors are buying Allena Pharmaceuticals stock?

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, Citadel Advisors LLC, Wells Fargo & Company MN and BlackRock Inc.. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $16.00.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $331.14 million. The company earns $-21,650,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.


MarketBeat Community Rating for Allena Pharmaceuticals (ALNA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allena Pharmaceuticals (NASDAQ:ALNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Allena Pharmaceuticals in the last 12 months. Their average twelve-month price target is $32.90, suggesting that the stock has a possible upside of 105.63%. The high price target for ALNA is $61.00 and the low price target for ALNA is $21.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.90$35.25$24.6667N/A
Price Target Upside: 105.63% upside183.59% upside140.65% upsideN/A

Allena Pharmaceuticals (NASDAQ:ALNA) Consensus Price Target History

Price Target History for Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals (NASDAQ:ALNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2018B. RileyInitiated CoverageBuy ➝ Buy$23.50HighView Rating Details
4/2/2018Roth CapitalInitiated CoverageBuy ➝ Buy$61.00HighView Rating Details
3/28/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$22.00 ➝ $21.00HighView Rating Details
3/28/2018WedbushReiterated RatingOutperform$37.00HighView Rating Details
11/27/2017CowenInitiated CoverageOutperformHighView Rating Details
11/27/2017Jefferies GroupInitiated CoverageBuy$22.00HighView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Allena Pharmaceuticals (NASDAQ:ALNA) Earnings History and Estimates Chart

Earnings by Quarter for Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals (NASDAQ:ALNA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.64)
2019 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.38)($0.38)($0.38)
Q2 20181($0.40)($0.40)($0.40)
Q3 20181($0.41)($0.41)($0.41)
Q4 20181($0.45)($0.45)($0.45)
Q1 20191($0.44)($0.44)($0.44)
Q2 20191($0.45)($0.45)($0.45)
Q3 20191($0.47)($0.47)($0.47)
Q4 20191($0.47)($0.47)($0.47)

Allena Pharmaceuticals (NASDAQ ALNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.4280)($0.38)ViewN/AView Earnings Details
3/27/2018Q4 2017($0.54)($0.48)ViewN/AView Earnings Details
12/14/2017Q3 2017($0.38)($3.49)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Allena Pharmaceuticals (NASDAQ:ALNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Allena Pharmaceuticals (NASDAQ ALNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 36.70%
Institutional Ownership Percentage: 84.11%
Insider Trading History for Allena Pharmaceuticals (NASDAQ:ALNA)
Insider Trading History for Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals (NASDAQ ALNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Bessemer Venture Partners ViiMajor ShareholderBuy36,000$14.00$504,000.00View SEC Filing  
11/6/2017James N TopperDirectorBuy500,000$14.00$7,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allena Pharmaceuticals (NASDAQ ALNA) News Headlines

Source:
DateHeadline
 Brokerages Expect Allena Pharmaceuticals (ALNA) to Post -$0.39 Earnings Per Share Brokerages Expect Allena Pharmaceuticals (ALNA) to Post -$0.39 Earnings Per Share
www.americanbankingnews.com - May 17 at 5:31 PM
Allena Pharmaceuticals (ALNA) Upgraded by Zacks Investment Research to HoldAllena Pharmaceuticals (ALNA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 11 at 5:43 PM
Wedbush Comments on Allena Pharmaceuticals Q2 2018 Earnings (ALNA)Wedbush Comments on Allena Pharmaceuticals' Q2 2018 Earnings (ALNA)
www.americanbankingnews.com - May 11 at 9:30 AM
Research Analysts Issue Forecasts for Allena Pharmaceuticals Q1 2019 Earnings (ALNA)Research Analysts Issue Forecasts for Allena Pharmaceuticals' Q1 2019 Earnings (ALNA)
www.americanbankingnews.com - May 10 at 8:52 AM
FY2018 EPS Estimates for Allena Pharmaceuticals Lowered by Analyst (ALNA)FY2018 EPS Estimates for Allena Pharmaceuticals Lowered by Analyst (ALNA)
www.americanbankingnews.com - May 10 at 8:41 AM
Allena Pharmaceuticals (ALNA) Announces  Earnings ResultsAllena Pharmaceuticals (ALNA) Announces Earnings Results
www.americanbankingnews.com - May 9 at 3:35 PM
Form 10-Q Allena Pharmaceuticals, For: Mar 31Form 10-Q Allena Pharmaceuticals, For: Mar 31
www.streetinsider.com - May 9 at 9:22 AM
BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38
www.reuters.com - May 9 at 9:22 AM
Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business UpdateAllena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 8 at 9:15 AM
Allena Pharmaceuticals (ALNA) Raised to Hold at ValuEngineAllena Pharmaceuticals (ALNA) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM
Allena Pharmaceuticals (ALNA) Expected to Announce Earnings of -$0.45 Per ShareAllena Pharmaceuticals (ALNA) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 30 at 3:16 AM
Allena Pharmaceuticals (ALNA) Receives Consensus Rating of "Buy" from AnalystsAllena Pharmaceuticals (ALNA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 29 at 3:30 PM
B. Riley Weighs in on Allena Pharmaceuticals FY2018 Earnings (ALNA)B. Riley Weighs in on Allena Pharmaceuticals' FY2018 Earnings (ALNA)
www.americanbankingnews.com - April 27 at 9:20 AM
Benzingas Top Upgrades, Downgrades For April 25, 2018Benzinga's Top Upgrades, Downgrades For April 25, 2018
www.benzinga.com - April 26 at 4:34 PM
Allena Pharmaceuticals (ALNA) Research Coverage Started at B. RileyAllena Pharmaceuticals (ALNA) Research Coverage Started at B. Riley
www.americanbankingnews.com - April 25 at 9:22 AM
Allena Pharmaceuticals Lock-Up Period Set To Expire  on May 1st (NASDAQ:ALNA)Allena Pharmaceuticals' Lock-Up Period Set To Expire on May 1st (NASDAQ:ALNA)
www.americanbankingnews.com - April 24 at 1:16 AM
Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
finance.yahoo.com - April 21 at 9:11 AM
 Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) Will Announce Earnings of -$0.45 Per Share Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 13 at 5:21 AM
Allena Pharmaceuticals (ALNA) Enters Overbought TerritoryAllena Pharmaceuticals (ALNA) Enters Overbought Territory
finance.yahoo.com - April 4 at 4:55 PM
Allena Pharmaceuticals Inc (ALNA) Receives Consensus Rating of "Hold" from AnalystsAllena Pharmaceuticals Inc (ALNA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 3:38 PM
Roth Capital Begins Coverage on Allena Pharmaceuticals (ALNA)Roth Capital Begins Coverage on Allena Pharmaceuticals (ALNA)
www.americanbankingnews.com - April 2 at 9:34 AM
Allena Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.38) Per Share (ALNA)Allena Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.38) Per Share (ALNA)
www.americanbankingnews.com - March 30 at 6:50 AM
Allena Pharmaceuticals (ALNA) PT Lowered to $21.00Allena Pharmaceuticals (ALNA) PT Lowered to $21.00
www.americanbankingnews.com - March 28 at 10:48 AM
Allena Pharmaceuticals (ALNA) Posts  Earnings Results, Beats Expectations By $0.06 EPSAllena Pharmaceuticals (ALNA) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - March 28 at 10:48 AM
Allena Pharmaceuticals (ALNA) Earns "Outperform" Rating from WedbushAllena Pharmaceuticals (ALNA) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 28 at 9:16 AM
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateAllena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 27 at 9:45 AM
Zacks: Brokerages Expect Allena Pharmaceuticals Inc (ALNA) Will Post Earnings of -$0.27 Per ShareZacks: Brokerages Expect Allena Pharmaceuticals Inc (ALNA) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - March 27 at 5:21 AM
ValuEngine Upgrades Allena Pharmaceuticals (ALNA) to "Sell"ValuEngine Upgrades Allena Pharmaceuticals (ALNA) to "Sell"
www.americanbankingnews.com - March 25 at 9:16 PM
Allena Pharmaceuticals Inc (ALNA) Given Average Recommendation of "Hold" by BrokeragesAllena Pharmaceuticals Inc (ALNA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 4:17 PM
-$0.27 Earnings Per Share Expected for Allena Pharmaceuticals Inc (ALNA) This Quarter-$0.27 Earnings Per Share Expected for Allena Pharmaceuticals Inc (ALNA) This Quarter
www.americanbankingnews.com - March 9 at 11:08 PM
Allena Pharmaceuticals (ALNA) "Buy" Rating Reiterated at WedbushAllena Pharmaceuticals' (ALNA) "Buy" Rating Reiterated at Wedbush
www.americanbankingnews.com - March 9 at 4:54 PM
State’s biotech IPO class of 2017 gets mixed reviews from investorsState’s biotech IPO class of 2017 gets mixed reviews from investors
www.bizjournals.com - March 8 at 9:40 AM
Allena Pharmaceuticals (ALNA) Initiates First Phase 3 Trial for ALLN-177 in Patients with EntericAllena Pharmaceuticals (ALNA) Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric
www.streetinsider.com - March 7 at 5:23 PM
Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care ConferenceAllena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 9:28 AM
Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric HyperoxaluriaAllena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
finance.yahoo.com - March 6 at 9:13 AM
Frazier Management LLC Purchases New Stake in Allena Pharmaceuticals Inc (ALNA)Frazier Management LLC Purchases New Stake in Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - March 5 at 8:00 AM
Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?
finance.yahoo.com - February 23 at 5:02 PM
Allena Pharmaceuticals Inc (ALNA) Expected to Announce Earnings of -$0.27 Per ShareAllena Pharmaceuticals Inc (ALNA) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - February 21 at 5:22 AM
Pharmstandard International S.A. Buys Allena Pharmaceuticals IncPharmstandard International S.A. Buys Allena Pharmaceuticals Inc
finance.yahoo.com - February 15 at 8:39 AM
Jefferies Group Weighs in on Allena Pharmaceuticals Incs FY2017 Earnings (ALNA)Jefferies Group Weighs in on Allena Pharmaceuticals Inc's FY2017 Earnings (ALNA)
www.americanbankingnews.com - February 15 at 7:56 AM
Allena Pharmaceuticals Inc (ALNA) Given Consensus Rating of "Hold" by AnalystsAllena Pharmaceuticals Inc (ALNA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 13 at 5:52 PM
Allena Pharmaceuticals (ALNA) Downgraded to "Sell" at Zacks Investment ResearchAllena Pharmaceuticals (ALNA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 13 at 4:16 PM
Wedbush Comments on Allena Pharmaceuticals Incs FY2022 Earnings (ALNA)Wedbush Comments on Allena Pharmaceuticals Inc's FY2022 Earnings (ALNA)
www.americanbankingnews.com - February 9 at 6:30 PM
 Analysts Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA) Analysts Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - February 1 at 1:28 AM
 Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) to Post -$0.33 Earnings Per Share Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - January 18 at 7:14 AM
 Brokerages Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA) Brokerages Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - January 17 at 5:42 AM
Zacks: Analysts Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)Zacks: Analysts Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - January 2 at 9:42 PM
Comparing Allena Pharmaceuticals (ALNA) & The CompetitionComparing Allena Pharmaceuticals (ALNA) & The Competition
www.americanbankingnews.com - December 20 at 9:28 PM
Wedbush Equities Analysts Increase Earnings Estimates for Allena Pharmaceuticals Inc (ALNA)Wedbush Equities Analysts Increase Earnings Estimates for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - December 20 at 9:56 AM
Wedbush Reaffirms Buy Rating for Allena Pharmaceuticals (ALNA)Wedbush Reaffirms Buy Rating for Allena Pharmaceuticals (ALNA)
www.americanbankingnews.com - December 18 at 8:26 PM

SEC Filings

Allena Pharmaceuticals (NASDAQ:ALNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allena Pharmaceuticals (NASDAQ:ALNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allena Pharmaceuticals (NASDAQ ALNA) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.